Dogma Therapeutics

Dogma Therapeutics has discovered true small-molecule inhibitors of PCSK9 function, which are orally bioavailable in multiple preclinical species. Guided by high-resolution X-ray structures of dozens of molecules binding to PCSK9, Dogma Therapeutics employed structure-based design to achieve picomolar affinity.